bumetanide has been researched along with Cardiac Failure in 76 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of acetazolamide on natriuresis, decongestion, kidney function and neurohumoral activation in acute heart failure (AHF)." | 9.30 | Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. ( Ameloot, K; Droogné, W; Dupont, M; Haemels, V; Martens, P; Mullens, W; Penders, J; Tang, WHW; Verbrugge, FH, 2019) |
| "Four healthy subjects and six patients with congestive heart failure (CHF) were given 3 mg oral and intravenous doses of bumetanide in a random crossover fashion." | 9.06 | Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. ( Cook, JA; Cornish, LA; Hyneck, ML; Nicklas, JM; Smith, DE; Tankanow, RM, 1988) |
| " bumetanide (25 micrograms kg-1) were prospectively studied in 24 patients with angiographically documented coronary artery disease and either acute exercise-induced (Group I, n = 12) or chronic (Group II, n = 12) heart failure." | 9.06 | Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure. ( Frais, MA; Muller, P; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987) |
| "Forty elderly patients, aged 68 to 89 years, with congestive cardiac failure, who were attending a hospital out-patients department, entered an open, parallel group, comparative study of two diuretic combinations, 40 mg frusemide plus 5 mg amiloride per tablet and 0." | 9.06 | An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients. ( Allman, S; Bailey, R; Crawford, RJ; Martin, A; Ramsay, F, 1988) |
| "The efficacy and safety of oral bumetanide, a pharmacologically new diuretic was compared with that of furosemide in 30 patients suffering from congestive cardiac failure and other edema states." | 9.05 | A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. ( Sagar, S; Sharma, BK; Sharma, PL; Wahi, PL, 1984) |
| "0 mg) and to furosemide (40 and 80 mg) in 20 patients with stable, compensated congestive heart failure (CHF), comparing the two drugs and, in addition, examining differences from normal subjects." | 9.05 | Bumetanide and furosemide in heart failure. ( Anderson, S; Brater, DC; Burdette, A; Day, B, 1984) |
| "The additive natriuretic and diuretic effects of theophylline ethylenediamine and of bendroflumethiazide have been compared in permutation trial tests in patients with advanced congestive heart failure receiving long-term treatment with the highly potent diuretic, bumetanide." | 9.04 | Comparative natriuretic and diuretic efficacy of theophylline ethylenediamine and of bendroflumethiazide during long-term treatment with the potent diuretic bumetanide. Permutation trial tests in patients with congestive heart failure. ( Olesen, KH; Sigurd, B, 1978) |
| "Bumetanide, a new diuretic exerting its major effect on the ascending limb of the loop of Henle, was evaluated in 20 patients with congestive heart failure." | 9.04 | Bumetanide in congestive heart failure. ( Augoustakis, D; Christensen, O; Kourouklis, C, 1976) |
| "1 This study has compared the diuresis produced by a single oral administration of 6 mg piretanide, 9 mg piretanide and 1 mg bumetanide in a group of nine patients with cardiac failure using a balanced randomized design." | 9.04 | A single dose comparison of piretanide and bumetanide in congestive cardiac failure. ( Dombey, SL; Homeida, M; Roberts, CJ, 1979) |
| "Continuous intravenous (IV) infusion bumetanide has been associated with severe myalgia in case reports, and the package labeling lists a reported incidence of 0." | 7.91 | Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure. ( Chinaeke, EE; Cox, ZL; Lenihan, DJ; Lu, K; Merritt, TE; Xiong, L, 2019) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 7.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "To evaluate the effect of bumetanide, quinapril and a low-sodium diet on clinical response tolerance and side-effects on dogs with moderate congestive heart failure." | 7.71 | Effect of short-term treatment with bumetanide, quinapril and low-sodium diet on dogs with moderate congestive heart failure. ( Corbera, JA; Martinez-Alcaine, MA; Montoya, JA; Ynaraja, E, 2001) |
| "Two hundred and thirty-three patients (66 males and 167 females), aged 24 to 92 years, with congestive cardiac failure were entered into a long-term study to evaluate the efficacy and tolerability of treatment with a fixed dose combination tablet containing 1 mg bumetanide and 5 mg amiloride." | 7.68 | Bumetanide/amiloride ('Burinex A'): a new combined preparation for the control of patients with congestive cardiac failure. ( Hughes, IW; Lustman, F, 1990) |
| " We therefore measured lymphocyte free Mg2+ concentrations in patients with congestive cardiac failure treated with loop diuretics or a frusemide/amiloride mixture (Frumil) and compared them with control subjects." | 7.68 | Intracellular free magnesium in lymphocytes from patients with congestive cardiac failure treated with loop diuretics with and without amiloride. ( Brochwicz-Lewinski, MJ; Davies, JE; Garrido, MC; Ng, LL; Tan, LB, 1992) |
| "The hemodynamic variations brought about by the single intravenous infection of 0,5 mg bumetanide have been studied in 7 patients with chronic ischemic heart disease and in 3 patients with non-obstructive hypertrophic cardiomyopathy, all of them in congestive heart failure." | 7.66 | [Hemodynamic changes produced by intravenous bumetanide in congestive heart failure]. ( Lomanto, B; Rossi, A; Ziacchi, V, 1981) |
| "The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied." | 7.65 | Bumetanide in heart failure in infancy. ( Lam, LK; Ward, OC, 1977) |
| "It is recommended in severe congestive heart failure (HF)." | 6.71 | Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. ( Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005) |
| "Mild congestive cardiac failure symptoms (raised jugular venous pressure, oedema and dyspnoea at rest and on effort) were controlled in 9/10 patients receiving frusemide/amiloride but two patients receiving bumetanide/potassium chloride still had mild oedema after 8 weeks." | 6.67 | An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/potassium chloride in the treatment of mild congestive cardiac failure. ( Allman, S; Dalton, K; Finnamore, VP; Latta, D, 1990) |
| "Bumetanide is a potent 'loop' diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and in forced diuresis during and after surgery." | 6.15 | Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. ( Heel, RC; Ward, A, 1984) |
| "To investigate the effects of acetazolamide on natriuresis, decongestion, kidney function and neurohumoral activation in acute heart failure (AHF)." | 5.30 | Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. ( Ameloot, K; Droogné, W; Dupont, M; Haemels, V; Martens, P; Mullens, W; Penders, J; Tang, WHW; Verbrugge, FH, 2019) |
| "Patients with severe congestive heart failure (New York Heart Association [NYHA] functional classes III-IV) often can tolerate only low doses of angiotensin-converting enzyme (ACE) inhibitors because pronounced hypotension caused by additional ACE inhibitor increments may decrease renal perfusion." | 5.29 | Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. ( Donker, AJ; Nauta, JJ; van Vliet, AA; Verheugt, FW, 1993) |
| "Bumetanide2 is a new diuretic with a rapid onset and short duration of action." | 5.25 | Bumetanide: A preliminary report of its pharmacological properties and therapeutic efficacy in oedema. ( Avery, GS; Brogden, RN; Speight, TM, 1975) |
| "We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial." | 5.19 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. ( Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014) |
| "Eight patients with mild heart failure were treated in random order for 1 week with 2 mg bumethanide at 0800 and 1200 (treatment 1) h, 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2) and 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3) h." | 5.07 | A comparison of three diuretic regimens in heart failure. ( Andreasen, F; Bech, OM; Bruun, P; Diamant, B; Eriksen, UH; Guul, SJ; Hartling, OJ; Hvidt, S; Kahr, O; Nielsen, LP, 1993) |
| "Four healthy subjects and six patients with congestive heart failure (CHF) were given 3 mg oral and intravenous doses of bumetanide in a random crossover fashion." | 5.06 | Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. ( Cook, JA; Cornish, LA; Hyneck, ML; Nicklas, JM; Smith, DE; Tankanow, RM, 1988) |
| "Forty elderly patients, aged 68 to 89 years, with congestive cardiac failure, who were attending a hospital out-patients department, entered an open, parallel group, comparative study of two diuretic combinations, 40 mg frusemide plus 5 mg amiloride per tablet and 0." | 5.06 | An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients. ( Allman, S; Bailey, R; Crawford, RJ; Martin, A; Ramsay, F, 1988) |
| " bumetanide (25 micrograms kg-1) were prospectively studied in 24 patients with angiographically documented coronary artery disease and either acute exercise-induced (Group I, n = 12) or chronic (Group II, n = 12) heart failure." | 5.06 | Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure. ( Frais, MA; Muller, P; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987) |
| "The clinical use of continuous bumetanide infusion for acute heart failure and volume overload is common." | 5.05 | Treatment outcomes of bumetanide continuous infusion: A systematic review and meta-analysis. ( Cheungpasitporn, W; Dimech, CT; Hansrivijit, P; Khanal, R; Techorueangwiwat, C; Thongprayoon, C, 2020) |
| "0 mg) and to furosemide (40 and 80 mg) in 20 patients with stable, compensated congestive heart failure (CHF), comparing the two drugs and, in addition, examining differences from normal subjects." | 5.05 | Bumetanide and furosemide in heart failure. ( Anderson, S; Brater, DC; Burdette, A; Day, B, 1984) |
| "The efficacy and safety of oral bumetanide, a pharmacologically new diuretic was compared with that of furosemide in 30 patients suffering from congestive cardiac failure and other edema states." | 5.05 | A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. ( Sagar, S; Sharma, BK; Sharma, PL; Wahi, PL, 1984) |
| "Bumetanide, a new diuretic exerting its major effect on the ascending limb of the loop of Henle, was evaluated in 20 patients with congestive heart failure." | 5.04 | Bumetanide in congestive heart failure. ( Augoustakis, D; Christensen, O; Kourouklis, C, 1976) |
| "The additive natriuretic and diuretic effects of theophylline ethylenediamine and of bendroflumethiazide have been compared in permutation trial tests in patients with advanced congestive heart failure receiving long-term treatment with the highly potent diuretic, bumetanide." | 5.04 | Comparative natriuretic and diuretic efficacy of theophylline ethylenediamine and of bendroflumethiazide during long-term treatment with the potent diuretic bumetanide. Permutation trial tests in patients with congestive heart failure. ( Olesen, KH; Sigurd, B, 1978) |
| "1 This study has compared the diuresis produced by a single oral administration of 6 mg piretanide, 9 mg piretanide and 1 mg bumetanide in a group of nine patients with cardiac failure using a balanced randomized design." | 5.04 | A single dose comparison of piretanide and bumetanide in congestive cardiac failure. ( Dombey, SL; Homeida, M; Roberts, CJ, 1979) |
| "Continuous intravenous (IV) infusion bumetanide has been associated with severe myalgia in case reports, and the package labeling lists a reported incidence of 0." | 3.91 | Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure. ( Chinaeke, EE; Cox, ZL; Lenihan, DJ; Lu, K; Merritt, TE; Xiong, L, 2019) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 3.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "To evaluate the effect of bumetanide, quinapril and a low-sodium diet on clinical response tolerance and side-effects on dogs with moderate congestive heart failure." | 3.71 | Effect of short-term treatment with bumetanide, quinapril and low-sodium diet on dogs with moderate congestive heart failure. ( Corbera, JA; Martinez-Alcaine, MA; Montoya, JA; Ynaraja, E, 2001) |
| " We therefore measured lymphocyte free Mg2+ concentrations in patients with congestive cardiac failure treated with loop diuretics or a frusemide/amiloride mixture (Frumil) and compared them with control subjects." | 3.68 | Intracellular free magnesium in lymphocytes from patients with congestive cardiac failure treated with loop diuretics with and without amiloride. ( Brochwicz-Lewinski, MJ; Davies, JE; Garrido, MC; Ng, LL; Tan, LB, 1992) |
| "Two hundred and thirty-three patients (66 males and 167 females), aged 24 to 92 years, with congestive cardiac failure were entered into a long-term study to evaluate the efficacy and tolerability of treatment with a fixed dose combination tablet containing 1 mg bumetanide and 5 mg amiloride." | 3.68 | Bumetanide/amiloride ('Burinex A'): a new combined preparation for the control of patients with congestive cardiac failure. ( Hughes, IW; Lustman, F, 1990) |
| "The hemodynamic variations brought about by the single intravenous infection of 0,5 mg bumetanide have been studied in 7 patients with chronic ischemic heart disease and in 3 patients with non-obstructive hypertrophic cardiomyopathy, all of them in congestive heart failure." | 3.66 | [Hemodynamic changes produced by intravenous bumetanide in congestive heart failure]. ( Lomanto, B; Rossi, A; Ziacchi, V, 1981) |
| "The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied." | 3.65 | Bumetanide in heart failure in infancy. ( Lam, LK; Ward, OC, 1977) |
| "Forty patients with congestive heart failure or hypertensive heart disease were given long-term maintenance treatment with a combined bumetanide/slow-release potassium supplement preparation ('Burinex K')." | 3.65 | Patient tolerance of long-term diuretic/potassium supplement therapy. ( Singh, BB; Watt, DA, 1976) |
| "Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment." | 2.87 | Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. ( Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV, 2018) |
| "It is recommended in severe congestive heart failure (HF)." | 2.71 | Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. ( Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005) |
| " Eight hours after dosing began, we administered approximately 80 mEq sodium intravenously and examined its excretion over 4 hours." | 2.68 | Role of duration of diuretic effect in preventing sodium retention. ( Becker, PK; Brater, DC; Ferguson, JA; Gorski, JC; Rudy, DW; Sundblad, KJ, 1997) |
| "Mild congestive cardiac failure symptoms (raised jugular venous pressure, oedema and dyspnoea at rest and on effort) were controlled in 9/10 patients receiving frusemide/amiloride but two patients receiving bumetanide/potassium chloride still had mild oedema after 8 weeks." | 2.67 | An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/potassium chloride in the treatment of mild congestive cardiac failure. ( Allman, S; Dalton, K; Finnamore, VP; Latta, D, 1990) |
| "In a random crossover study in general practice, sixty patients with heart failure were given one week's maintenance treatment with the recommended dosage of Burinex K or Lasix+K." | 2.64 | Patient acceptability of two diuretic/potassium supplement preparations. ( Bennion-Pedley, J; Donald, JF; Gould, CH; Lomas, DM; Postlethwaite, DL; Rivlin, R, 1976) |
| "Hypoalbuminemia is believed to decrease diuretic effectiveness and contribute to diuretic resistance that is observed in patients with nephrotic syndrome." | 1.39 | The effect of continuous infusion loop diuretics in patients with acute decompensated heart failure with hypoalbuminemia. ( Bleske, BE; Clark, MM; Dorsch, MP; Wu, AH, 2013) |
| "Treatment of congestive heart failure has changed dramatically during the past 20 years, but diuretic drugs remain an essential component." | 1.31 | Diuretic therapy and resistance in congestive heart failure. ( Ellison, DH, 2001) |
| "Patients with severe congestive heart failure (New York Heart Association [NYHA] functional classes III-IV) often can tolerate only low doses of angiotensin-converting enzyme (ACE) inhibitors because pronounced hypotension caused by additional ACE inhibitor increments may decrease renal perfusion." | 1.29 | Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. ( Donker, AJ; Nauta, JJ; van Vliet, AA; Verheugt, FW, 1993) |
| "03 L/kg) and the elimination half-life (13." | 1.28 | Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ( Fasules, JW; Kearns, GL; Taylor, BJ; Wells, TG, 1992) |
| "In advanced heart failure, mitral regurgitation increases the burden of the failing ventricle and decreases effective stroke volume." | 1.28 | Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. ( Belil, D; Brunken, RC; Grover-McKay, M; Schelbert, HR; Schwaiger, M; Stevenson, LW; Tillisch, JH, 1990) |
| "Bumetanide2 is a new diuretic with a rapid onset and short duration of action." | 1.25 | Bumetanide: A preliminary report of its pharmacological properties and therapeutic efficacy in oedema. ( Avery, GS; Brogden, RN; Speight, TM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (48.68) | 18.7374 |
| 1990's | 12 (15.79) | 18.2507 |
| 2000's | 10 (13.16) | 29.6817 |
| 2010's | 14 (18.42) | 24.3611 |
| 2020's | 3 (3.95) | 2.80 |
| Authors | Studies |
|---|---|
| Doggrell, SA | 1 |
| Hansrivijit, P | 1 |
| Techorueangwiwat, C | 1 |
| Khanal, R | 1 |
| Dimech, CT | 1 |
| Thongprayoon, C | 1 |
| Cheungpasitporn, W | 1 |
| Girerd, N | 1 |
| Aubry, M | 1 |
| Lantelme, P | 1 |
| Huttin, O | 1 |
| Rossignol, P | 1 |
| Hallow, KM | 1 |
| Helmlinger, G | 1 |
| Greasley, PJ | 1 |
| McMurray, JJV | 1 |
| Boulton, DW | 1 |
| Täger, T | 1 |
| Fröhlich, H | 1 |
| Grundtvig, M | 1 |
| Seiz, M | 1 |
| Schellberg, D | 1 |
| Goode, K | 1 |
| Kazmi, S | 1 |
| Hole, T | 1 |
| Katus, HA | 1 |
| Atar, D | 1 |
| Cleland, JGF | 1 |
| Agewall, S | 1 |
| Clark, AL | 1 |
| Frankenstein, L | 1 |
| Verbrugge, FH | 3 |
| Martens, P | 1 |
| Ameloot, K | 1 |
| Haemels, V | 1 |
| Penders, J | 3 |
| Dupont, M | 3 |
| Tang, WHW | 1 |
| Droogné, W | 2 |
| Mullens, W | 3 |
| Xiong, L | 1 |
| Chinaeke, EE | 1 |
| Lu, K | 1 |
| Lenihan, DJ | 1 |
| Merritt, TE | 1 |
| Cox, ZL | 1 |
| Bleske, BE | 1 |
| Clark, MM | 1 |
| Wu, AH | 1 |
| Dorsch, MP | 1 |
| Ng, TM | 1 |
| Konopka, E | 1 |
| Hyderi, AF | 1 |
| Hshieh, S | 1 |
| Tsuji, Y | 1 |
| Kim, BJ | 1 |
| Han, SY | 1 |
| Phan, DH | 1 |
| Jeng, AI | 1 |
| Lou, M | 1 |
| Elkayam, U | 1 |
| Valente, MA | 1 |
| Voors, AA | 2 |
| Damman, K | 2 |
| Van Veldhuisen, DJ | 1 |
| Massie, BM | 1 |
| O'Connor, CM | 1 |
| Metra, M | 1 |
| Ponikowski, P | 1 |
| Teerlink, JR | 1 |
| Cotter, G | 1 |
| Davison, B | 1 |
| Cleland, JG | 1 |
| Givertz, MM | 2 |
| Bloomfield, DM | 1 |
| Fiuzat, M | 1 |
| Dittrich, HC | 1 |
| Hillege, HL | 1 |
| Jacobs, S | 1 |
| Waelbers, V | 1 |
| Bossche, KV | 1 |
| Bollen, H | 1 |
| Geens, J | 1 |
| Rega, F | 1 |
| Burkhoff, D | 1 |
| Meyns, B | 1 |
| Nijst, P | 2 |
| Tang, WH | 3 |
| Shisler, D | 1 |
| Austin, TM | 1 |
| Delpire, E | 1 |
| Sawyer, DB | 1 |
| Pandey, AK | 1 |
| Bertrand, PB | 1 |
| Dens, J | 1 |
| Verhaert, D | 1 |
| Vandervoort, P | 1 |
| Testani, JM | 2 |
| Hanberg, JS | 2 |
| Cheng, S | 1 |
| Rao, V | 1 |
| Onyebeke, C | 1 |
| Laur, O | 1 |
| Kula, A | 1 |
| Chen, M | 1 |
| Wilson, FP | 1 |
| Darlington, A | 1 |
| Bellumkonda, L | 2 |
| Jacoby, D | 1 |
| Parikh, CR | 1 |
| Ter Maaten, JM | 1 |
| Rao, VS | 1 |
| Perry Wilson, F | 1 |
| Assefa, M | 1 |
| Sam Broughton, J | 1 |
| D'Ambrosi, J | 1 |
| Wilson Tang, WH | 1 |
| Ellison, DH | 2 |
| De Smedt, RH | 1 |
| Jaarsma, T | 1 |
| van den Broek, SA | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Mielniczuk, LM | 1 |
| Tsang, SW | 1 |
| Desai, AS | 1 |
| Nohria, A | 1 |
| Lewis, EF | 1 |
| Fang, JC | 1 |
| Baughman, KL | 1 |
| Stevenson, LW | 2 |
| Lapsia, V | 1 |
| Kazory, A | 1 |
| Earl, G | 1 |
| Davenport, J | 1 |
| Narula, J | 1 |
| Rosenberg, J | 1 |
| Gustafsson, F | 1 |
| Galatius, S | 1 |
| Hildebrandt, PR | 1 |
| Eshaghian, S | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Chuen, MJ | 1 |
| MacFadyen, RJ | 1 |
| Mehta, RL | 1 |
| Cantarovich, F | 1 |
| Shaw, A | 1 |
| Hoste, E | 1 |
| Murray, P | 1 |
| Sagar, S | 1 |
| Sharma, BK | 1 |
| Sharma, PL | 1 |
| Wahi, PL | 1 |
| Ward, A | 1 |
| Heel, RC | 1 |
| Brater, DC | 3 |
| Day, B | 1 |
| Burdette, A | 1 |
| Anderson, S | 1 |
| Misra, NP | 1 |
| Jain, SC | 1 |
| Maheshwari, J | 1 |
| Gabriel, R | 1 |
| Baylor, P | 1 |
| Humair, L | 1 |
| Ziacchi, V | 1 |
| Rossi, A | 1 |
| Lomanto, B | 1 |
| Mauro, G | 1 |
| Cantino, G | 1 |
| Vigiani, L | 1 |
| Pellerito, R | 1 |
| Bertola, D | 1 |
| Soragna, A | 1 |
| Varricchio, M | 1 |
| Spiezia, R | 1 |
| Giugliano, D | 1 |
| Torella, R | 1 |
| Giannetti, G | 1 |
| Brady, JA | 1 |
| Rock, CL | 1 |
| Horneffer, MR | 1 |
| van Vliet, AA | 1 |
| Donker, AJ | 1 |
| Nauta, JJ | 1 |
| Verheugt, FW | 1 |
| Silke, B | 2 |
| Andreasen, F | 1 |
| Eriksen, UH | 1 |
| Guul, SJ | 1 |
| Nielsen, LP | 1 |
| Bech, OM | 1 |
| Diamant, B | 1 |
| Kahr, O | 1 |
| Bruun, P | 1 |
| Hartling, OJ | 1 |
| Hvidt, S | 1 |
| Varriale, P | 1 |
| Mossavi, A | 1 |
| Ferguson, JA | 1 |
| Sundblad, KJ | 1 |
| Becker, PK | 1 |
| Gorski, JC | 1 |
| Rudy, DW | 1 |
| Martinez-Alcaine, MA | 1 |
| Ynaraja, E | 1 |
| Corbera, JA | 1 |
| Montoya, JA | 1 |
| Taylor, I | 1 |
| Watters, M | 1 |
| Kubik, MM | 2 |
| Bowers, E | 2 |
| Underwood, PN | 3 |
| Sigurd, B | 4 |
| Olesen, KH | 2 |
| Homeida, M | 1 |
| Roberts, CJ | 1 |
| Dombey, SL | 1 |
| Ward, OC | 1 |
| Lam, LK | 1 |
| Vichi, FL | 1 |
| de Oliveira, AC | 1 |
| Fariña, FR | 1 |
| Bernardes F, J | 1 |
| Martins, JD | 1 |
| Mazotti, L | 1 |
| Michalsen, H | 1 |
| Stokkeland, M | 1 |
| Ditlefsen, EM | 1 |
| Sangvik, K | 1 |
| Kourouklis, C | 1 |
| Christensen, O | 1 |
| Augoustakis, D | 1 |
| Bennion-Pedley, J | 1 |
| Donald, JF | 1 |
| Gould, CH | 1 |
| Lomas, DM | 1 |
| Postlethwaite, DL | 1 |
| Rivlin, R | 1 |
| Lawson, DH | 1 |
| Boddy, K | 1 |
| Gray, JM | 1 |
| Mahaffey, M | 1 |
| Mills, E | 1 |
| Johansson, BW | 1 |
| Hesse, B | 2 |
| Bollerup, AC | 1 |
| Valentin, N | 1 |
| Olsen, KH | 1 |
| Steiness, E | 1 |
| Leth, A | 1 |
| Hunter, KR | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Singh, BB | 1 |
| Watt, DA | 1 |
| Wells, TG | 1 |
| Fasules, JW | 1 |
| Taylor, BJ | 1 |
| Kearns, GL | 1 |
| Ng, LL | 1 |
| Garrido, MC | 1 |
| Davies, JE | 1 |
| Brochwicz-Lewinski, MJ | 1 |
| Tan, LB | 1 |
| Bourgain, C | 1 |
| Bienvenu, T | 1 |
| Crémieux, AC | 1 |
| Delage, A | 1 |
| Carbon, C | 1 |
| Latta, D | 1 |
| Finnamore, VP | 1 |
| Dalton, K | 1 |
| Allman, S | 2 |
| Hughes, IW | 1 |
| Lustman, F | 1 |
| Brunken, RC | 1 |
| Belil, D | 1 |
| Grover-McKay, M | 1 |
| Schwaiger, M | 1 |
| Schelbert, HR | 1 |
| Tillisch, JH | 1 |
| Wilken-Jensen, C | 1 |
| Ring-Larsen, H | 2 |
| Henriksen, JH | 2 |
| Clausen, J | 2 |
| Pals, H | 2 |
| Christensen, NJ | 2 |
| Wilken, C | 1 |
| Cook, JA | 1 |
| Smith, DE | 1 |
| Cornish, LA | 1 |
| Tankanow, RM | 1 |
| Nicklas, JM | 1 |
| Hyneck, ML | 1 |
| Chaudhuri, ML | 1 |
| Catania, J | 1 |
| Denisenko, BA | 1 |
| Gol'dberg, GA | 1 |
| Solov'eva, NN | 1 |
| Bichan, NA | 1 |
| Kashnikova, LG | 1 |
| Verma, SP | 1 |
| Reynolds, G | 1 |
| Muller, P | 1 |
| Frais, MA | 1 |
| Taylor, SH | 1 |
| Ramsay, F | 1 |
| Crawford, RJ | 1 |
| Bailey, R | 1 |
| Martin, A | 1 |
| Darlington, LG | 1 |
| Pines, A | 1 |
| Sreedharan, KS | 1 |
| Nandi, AR | 1 |
| Marsh, BT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure[NCT01973335] | Phase 4 | 34 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study[NCT04397302] | 652 participants (Actual) | Observational [Patient Registry] | 2019-01-13 | Completed | |||
| Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure[NCT02689180] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Effect of Thiamin Supplementation on Thiamin Status in Children With Heart Disease Receiving Diuretic Drugs: Randomized Controlled Trial[NCT03989700] | Phase 3 | 60 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| Efficacy of Aquapheresis in Patients Treated as Outpatients With Decompensated Heart Failure at a Veterans Hospital[NCT04572867] | 0 participants (Actual) | Interventional | 2021-06-08 | Withdrawn (stopped due to Due to low enrollment, COVID-19 pandemic causing suspension of most outpatient elective procedures, and no protected research time, Dr. Gelzer Bell is unable to continue this study.) | |||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For the acetazolamide arm of the study, the primary end-point is total natriuresis after 24 h (mmol). To assess this, urine is collected for 24 h after the first administration of diuretics according to the study protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L). Subsequently, patients receiving acetazolamide and low-dose loop diuretics (both the groups with and without upfront spironolactone together) are compared to patients not receiving acetazolamide but high-dose loop diuretics instead (both the groups with or without upfront spironolactone together) (NCT01973335)
Timeframe: 24h
| Intervention | mmol (Mean) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 324 |
| High-dose Loop Diuretics, Upfront Spironolactone | 300 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 211 |
| High-dose Loop Diuretics, no Spironolactone | 190 |
Relative NT-proBNP change (%) after 72 h compared to baseline. (NCT01973335)
Timeframe: 72h
| Intervention | percentage change from baseline (Mean) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | -20 |
| High-dose Loop Diuretics, Upfront Spironolactone | -11 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | -3 |
| High-dose Loop Diuretics, no Spironolactone | -6 |
Worsening renal function is defined as a rise in serum creatine >0.3 mg/dL or a >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula compared to baseline at any time point before 72 h. Serum creatinine values are assessed at three consecutive mornings after study inclusion. (NCT01973335)
Timeframe: 72h
| Intervention | Participants (Count of Participants) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 2 |
| High-dose Loop Diuretics, Upfront Spironolactone | 0 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 3 |
| High-dose Loop Diuretics, no Spironolactone | 0 |
At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma aldosterone levels. The highest value will constitute the peak plasma aldosterone concentration (ng/L). (NCT01973335)
Timeframe: 72h
| Intervention | ng/L (Median) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 196 |
| High-dose Loop Diuretics, Upfront Spironolactone | 234 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 302 |
| High-dose Loop Diuretics, no Spironolactone | 204 |
At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma renin activity. The highest value will constitute the peak plasma renin activity (ng/mL/h). (NCT01973335)
Timeframe: 72h
| Intervention | µg/L/h (Median) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 3.8 |
| High-dose Loop Diuretics, Upfront Spironolactone | 5.0 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 12.0 |
| High-dose Loop Diuretics, no Spironolactone | 2.5 |
Persistent renal impairment is defined as a persistently elevated serum creatine >0.3mg/dL or >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, above the baseline value of the patient and will be assessed on a scheduled follow-up appointment 4 weeks after hospital discharge. (NCT01973335)
Timeframe: 4 weeks after hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 3 |
| High-dose Loop Diuretics, Upfront Spironolactone | 1 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 0 |
| High-dose Loop Diuretics, no Spironolactone | 1 |
For the spironolactone arm of the study, the primary end-point is the incidence of either hypo- (serum potassium <3.5 mmol/L) or hyperkalemia (serum potassium >5.0 mmol/L) at any of 3 morning blood samples at consecutive days after randomization. Patients receiving upfront spironolactone (both the group receiving acetazolamide+low dose loop diuretics and the group receiving high-dose loop diuretic therapy) are compared with them receiving no spironolactone (both the group receiving acetazolamide+low dose loop diuretics and the group receiving high-dose loop diuretic therapy). (NCT01973335)
Timeframe: 72h
| Intervention | Participants (Count of Participants) |
|---|---|
| Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone | 1 |
| High-dose Loop Diuretics, Upfront Spironolactone | 2 |
| Acetazolamide/Low-dose Loop Diuretics, no Spironolactone | 5 |
| High-dose Loop Diuretics, no Spironolactone | 2 |
4 reviews available for bumetanide and Cardiac Failure
| Article | Year |
|---|---|
Treatment outcomes of bumetanide continuous infusion: A systematic review and meta-analysis.
Topics: Acute Kidney Injury; Bumetanide; Dose-Response Relationship, Drug; Duration of Therapy; Heart Failur | 2020 |
Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
Topics: Animals; Bumetanide; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Diuretics; Heart Failu | 1984 |
Central hemodynamic effects of diuretic therapy in chronic heart failure.
Topics: Bumetanide; Cardiac Output; Diuresis; Diuretics; Furosemide; Heart Failure; Hemodynamics; Humans; Mu | 1993 |
Disposition and response to bumetanide and furosemide.
Topics: Adult; Aged; Biological Availability; Bumetanide; Diuretics; Furosemide; Heart Failure; Humans; Kidn | 1986 |
30 trials available for bumetanide and Cardiac Failure
| Article | Year |
|---|---|
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Topics: Adult; Benzhydryl Compounds; Blood Volume; Bumetanide; Diuresis; Diuretics; Drug Combinations; Drug | 2018 |
Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
Topics: Acetazolamide; Adult; Aged; Bumetanide; Dose-Response Relationship, Drug; Drug Resistance; Drug Ther | 2019 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diur | 2014 |
Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Bumetanide; Diuretics; Drug Therapy, Combinati | 2005 |
A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bumetanide; Clinical Trials as Topic; Diuretics; Doub | 1984 |
Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
Topics: Animals; Bumetanide; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Diuretics; Heart Failu | 1984 |
Bumetanide and furosemide in heart failure.
Topics: Absorption; Adult; Aged; Bumetanide; Diuretics; Dose-Response Relationship, Drug; Female; Furosemide | 1984 |
Comparison of the chronic effects of bendrofluazide, bumetanide and frusemide on plasma biochemical variables.
Topics: Aged; Analysis of Variance; Bendroflumethiazide; Blood Chemical Analysis; Bumetanide; Clinical Trial | 1981 |
A comparison of three diuretic regimens in heart failure.
Topics: Aged; Aged, 80 and over; Bendroflumethiazide; Blood Volume; Bumetanide; Circadian Rhythm; Diuretics; | 1993 |
The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function?
Topics: Acute Disease; Acute Kidney Injury; Aged; Aged, 80 and over; Bumetanide; Diuretics; Dopamine; Dose-R | 1997 |
Role of duration of diuretic effect in preventing sodium retention.
Topics: Adult; Bumetanide; Cross-Over Studies; Diuretics; Female; Heart Failure; Humans; Infusions, Intraven | 1997 |
Comparison of separate versus simultaneous administration of potassium supplement with the diuretic bumetanide.
Topics: Aged; Bicarbonates; Bumetanide; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; H | 1977 |
Comparative natriuretic and diuretic efficacy of theophylline ethylenediamine and of bendroflumethiazide during long-term treatment with the potent diuretic bumetanide. Permutation trial tests in patients with congestive heart failure.
Topics: Bendroflumethiazide; Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Drug Evaluation; Dru | 1978 |
A single dose comparison of piretanide and bumetanide in congestive cardiac failure.
Topics: Aged; Bumetanide; Calcium; Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Male; | 1979 |
Longterm experience of the routine use of bumetanide.
Topics: Aged; Bumetanide; Clinical Trials as Topic; Coronary Disease; Diuretics; Female; Heart Failure; Huma | 1976 |
[Bumetanide (Burinex) --furosemide (Lasix). A comparative study in congestive heart failure].
Topics: Bumetanide; Clinical Trials as Topic; Diuretics; Drug Evaluation; Furosemide; Heart Failure; Humans | 1976 |
Bumetanide in congestive heart failure.
Topics: Bumetanide; Clinical Trials as Topic; Diuretics; Electrolytes; Heart Failure; Humans | 1976 |
Patient acceptability of two diuretic/potassium supplement preparations.
Topics: Aged; Bumetanide; Clinical Trials as Topic; Deglutition; Delayed-Action Preparations; Diuretics; Dru | 1976 |
[Bumetanide--a new potent diuretic for oral and intravenous use].
Topics: Bumetanide; Clinical Trials as Topic; Diuretics; Drug Evaluation; Furosemide; Heart Failure; Humans; | 1975 |
Investigations with intravenous bumetanide.
Topics: Adolescent; Adult; Aged; Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Female; Glomerul | 1975 |
Diuretic action of bumetanide in congestive heart failure.
Topics: Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Drug Evaluation; Glomerular Filtration Ra | 1975 |
Evaluation of once-daily versus twice-daily bumetanide in heart failure.
Topics: Aged; Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Dose-Response Relationship, Drug; H | 1975 |
An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/potassium chloride in the treatment of mild congestive cardiac failure.
Topics: Adult; Amiloride; Blood Pressure; Bumetanide; Diuretics; Drug Combinations; Female; Furosemide; Hear | 1990 |
[Effect of posture on the diuretic treatment of decompensated cirrhosis and heart failure].
Topics: Adult; Aged; Bumetanide; Diuretics; Female; Heart Failure; Humans; Liver Cirrhosis, Alcoholic; Male; | 1989 |
Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.
Topics: Adult; Aged; Aldosterone; Bumetanide; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; | 1986 |
Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Blood Proteins; Bumetanide; Diuretics; D | 1988 |
A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.
Topics: Aged; Aged, 80 and over; Blood Glucose; Bumetanide; Diuretics; Female; Furosemide; Glucose Tolerance | 1988 |
[Clinical study of the effectiveness of a new Russian diuretic buphenox (bumetanide) in cardiac insufficiency].
Topics: Adult; Aged; Bumetanide; Clinical Trials as Topic; Diuretics; Double-Blind Method; Heart Failure; Hu | 1988 |
Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure.
Topics: Acute Disease; Adult; Aged; Bumetanide; Chronic Disease; Clinical Trials as Topic; Diuretics; Electr | 1987 |
An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Amiloride; Bumetanide; Diuretics; Drug Combinations; Femal | 1988 |
43 other studies available for bumetanide and Cardiac Failure
| Article | Year |
|---|---|
A new role for an old drug: acetazolamide in decompensated heart failure.
Topics: Acetazolamide; Bumetanide; Diuretics; Heart Failure; Humans; Quality of Life; Treatment Outcome | 2023 |
Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bumetanide; Canrenoic Acid; Creatinine; Diures | 2021 |
Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis.
Topics: Aged; Blood Pressure; Bumetanide; Cause of Death; Europe; Female; Follow-Up Studies; Furosemide; Hea | 2019 |
Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure.
Topics: Bumetanide; Diuretics; Electronic Health Records; Female; Furosemide; Heart Failure; Humans; Inciden | 2019 |
The effect of continuous infusion loop diuretics in patients with acute decompensated heart failure with hypoalbuminemia.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Bumetanide; Creatinine; Diuretics; | 2013 |
Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.
Topics: Acute Disease; Adult; Aged; Blood Urea Nitrogen; Bumetanide; Cohort Studies; Diuretics; Drug Therapy | 2013 |
Evolution of renal function after partial and full mechanical support for chronic heart failure.
Topics: Adult; Aged; Bumetanide; Creatinine; Diuretics; Female; Heart Failure; Heart-Assist Devices; Humans; | 2014 |
Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.
Topics: Administration, Oral; Aged; Biomarkers; Bumetanide; Chlorides; Diuretics; Dose-Response Relationship | 2014 |
Syndrome of severe pain associated with a continuous bumetanide infusion.
Topics: Aged; Bumetanide; Diuretics; Female; Heart Failure; Humans; Hyperalgesia; Infusions, Intravenous; Mu | 2014 |
Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
Topics: Aged; Bumetanide; Cohort Studies; Diuretics; Female; Heart Failure; Humans; Male; Natriuresis; Prosp | 2015 |
Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.
Topics: Acute Disease; Administration, Intravenous; Aged; Biomarkers; Bumetanide; Drug Monitoring; Drug Resi | 2016 |
Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
Topics: Acute Disease; Administration, Intravenous; Biomarkers; Bumetanide; Dose-Response Relationship, Drug | 2017 |
Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report.
Topics: Aged; Anticonvulsants; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Heart Failure; Herpes Z | 2008 |
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diure | 2008 |
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diure | 2008 |
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diure | 2008 |
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diure | 2008 |
Loop diuretics for heart failure-associated hyponatremia.
Topics: Bumetanide; Female; Heart Failure; Humans; Hyponatremia; Middle Aged; Sodium; Sodium Potassium Chlor | 2010 |
Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics.
Topics: Aged; Bumetanide; Diuretics; Drug Hypersensitivity; Female; Furosemide; Heart Failure; Humans; Male | 2003 |
Relation of loop diuretic dose to mortality in advanced heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Resp | 2006 |
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Resp | 2006 |
Pharmacologic approaches for volume excess in acute kidney injury (AKI).
Topics: Acute Kidney Injury; Ascites; Bumetanide; Diuretics; Fluid Therapy; Furosemide; Heart Failure; Hepat | 2008 |
Bumetanide in congestive cardiac failure.
Topics: Bumetanide; Diuresis; Diuretics; Heart Failure; Humans | 1983 |
[Bumetanide in renal insufficiency].
Topics: Aged; Bumetanide; Diuretics; Female; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; L | 1982 |
[Hemodynamic changes produced by intravenous bumetanide in congestive heart failure].
Topics: Aged; Bumetanide; Diuretics; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged | 1981 |
[Clinical evaluation of bumetanide in the diuretic treatment of heart failure and liver cirrhosis].
Topics: Adult; Aged; Bumetanide; Diuresis; Diuretics; Electrolytes; Ethacrynic Acid; Female; Furosemide; Hea | 1981 |
[Clinical use of bumetanide].
Topics: Blood Pressure; Bumetanide; Diuresis; Diuretics; Edema; Electrolytes; Female; Heart Failure; Humans; | 1981 |
[Clinical evaluation of bumetanide in congestive heart failure].
Topics: Adult; Aged; Bumetanide; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged | 1980 |
Thiamin status, diuretic medications, and the management of congestive heart failure.
Topics: Adult; Aged; Bumetanide; Cross-Sectional Studies; Diet Records; Female; Food-Drug Interactions; Furo | 1995 |
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Bumetanide; Drug Resistance; Drug | 1993 |
Effect of short-term treatment with bumetanide, quinapril and low-sodium diet on dogs with moderate congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Bumetanide; Diet, Sodium-Restricted; Diuretics; D | 2001 |
Pulmonary oedema after ophthalmic regional anaesthesia in an unfasted patient undergoing elective surgery.
Topics: Aged; Anesthesia, Conduction; Bumetanide; Diuretics; Fasting; Female; Heart Failure; Humans; Intubat | 2001 |
Diuretic therapy and resistance in congestive heart failure.
Topics: Benzothiadiazines; Bumetanide; Diuretics; Drug Resistance; Drug Synergism; Drug Therapy, Combination | 2001 |
Diuretic therapy and resistance in congestive heart failure.
Topics: Benzothiadiazines; Bumetanide; Diuretics; Drug Resistance; Drug Synergism; Drug Therapy, Combination | 2001 |
Diuretic therapy and resistance in congestive heart failure.
Topics: Benzothiadiazines; Bumetanide; Diuretics; Drug Resistance; Drug Synergism; Drug Therapy, Combination | 2001 |
Diuretic therapy and resistance in congestive heart failure.
Topics: Benzothiadiazines; Bumetanide; Diuretics; Drug Resistance; Drug Synergism; Drug Therapy, Combination | 2001 |
The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.
Topics: Adult; Bumetanide; Diuretics; Drug Therapy, Combination; Ethylenediamines; Heart Failure; Humans; Lo | 1977 |
Bumetanide in heart failure in infancy.
Topics: Acute Disease; Bumetanide; Diuresis; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; In | 1977 |
[Bumetanide in the treatment of congestive heart failure and arterial hypertension].
Topics: Body Weight; Bumetanide; Diuresis; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Hype | 1978 |
Potassium supplements in patients receiving long-term diuretics for oedema.
Topics: Bendroflumethiazide; Body Composition; Bumetanide; Diuretics; Edema, Cardiac; Female; Furosemide; He | 1976 |
Bumetanide: A preliminary report of its pharmacological properties and therapeutic efficacy in oedema.
Topics: Animals; Ascites; Bumetanide; Diuresis; Dogs; Drug Incompatibility; Edema; Heart Failure; Humans; Ki | 1975 |
Patient tolerance of long-term diuretic/potassium supplement therapy.
Topics: Adult; Aged; Bumetanide; Diuretics; Drug Combinations; Female; Heart Diseases; Heart Failure; Humans | 1976 |
Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation.
Topics: Analysis of Variance; Bumetanide; Combined Modality Therapy; Diuresis; Extracorporeal Membrane Oxyge | 1992 |
Intracellular free magnesium in lymphocytes from patients with congestive cardiac failure treated with loop diuretics with and without amiloride.
Topics: Amiloride; Bumetanide; Cations, Divalent; Drug Therapy, Combination; Furosemide; Heart Failure; Huma | 1992 |
[Bumetanide as replacement therapy in furosemide-induced vasculitis].
Topics: Aged; Bumetanide; Female; Furosemide; Heart Failure; Humans; Vasculitis, Leukocytoclastic, Cutaneous | 1990 |
Bumetanide/amiloride ('Burinex A'): a new combined preparation for the control of patients with congestive cardiac failure.
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Bumetanide; Drug Administration Schedule; Drug Combinatio | 1990 |
Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure.
Topics: Bumetanide; Diuretics; Exercise; Female; Ferricyanides; Furosemide; Heart; Heart Failure; Humans; Ma | 1990 |
Study to compare the relative hyperuricaemic effects of frusemide and bumetanide.
Topics: Aged; Bumetanide; Diuretics; Edema; Female; Furosemide; Heart Failure; Humans; Hypertension; Male; M | 1986 |
A clinical assessment of bumetanide in patients not responding to other diuretics.
Topics: Aged; Bumetanide; Diuretics; Edema; Electrolytes; Female; Heart Failure; Humans; Male; Middle Aged; | 1974 |